FibroGen, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FGEN research report →
About the company
FibroGen, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and bringing to market therapies that address significant medical conditions currently lacking effective treatments. Among its pipeline, FibroGen is advancing Roxadustat, an orally administered small molecule that inhibits hypoxia inducible factor prolyl hydroxylases.
- CEO
- Thane Wettig
- IPO
- 2014
- Employees
- 225
- HQ
- San Francisco, CA, US
Price Chart
- Market Cap
- $36.69M
- P/E
- 0.18
- P/S
- 4.15
- P/B
- -0.70
- EV/EBITDA
- -0.23
- Div Yield
- 0.00%
- Gross Margin
- 45.11%
- Op Margin
- -603.83%
- Net Margin
- 2199.42%
- ROE
- -234.28%
- ROIC
- -55.02%
- Revenue
- $6.44M · -78.26%
- Net Income
- $183.45M · 485.57%
- EPS
- $45.37 · 9552.08%
- Op Income
- $-45,895,000
- FCF YoY
- 96.52%
- 52W High
- $21.95
- 52W Low
- $4.85
- 50D MA
- $9.14
- 200D MA
- $8.84
- Beta
- 0.77
- Avg Volume
- 33.23K
Get TickerSpark's AI analysis on FGEN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 31, 22 | Wettig Thane | other | 0 |
Our FGEN coverage
Recent articles, reports, and earnings notes.
No research on FGEN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FGEN report →Similar companies
Peers in the same neighborhood.